
Ferdy S van Geest , Stefan Groeneweg , Erica T van den Akker , Iuliu Bacos , Diana Barca , Sjoerd A A van den Berg , Enrico Bertini , Doris Brunner , Nicola Brunetti-Pierri , Marco Cappa , Gerarda Cappuccio , Krishna Chatterjee , Alexander D Chesover 14, Peter Christian , Régis Coutant, Dana Craiu Patricia Crock Cheyenne Dewey , Alice Dica , Paul Dimitri Rachana Dubey , Anina Enderli , Jan Fairchild , Jonathan Gallichan , Luigi R Garibaldi , Belinda George , Annette Hackenberg , Bianka Heinrich , Tony Huynh , Anna Kłosowska, Amy Lawson-Yuen, Michaela Linder-Lucht, Greta Lyons , Felipe Monti Lora , Carla Moran , Katalin E Müller, Laura Paone , Praveen G Paul , Michel Polak , Francesco Porta , Christina Reinauer, Yolanda B de Rijke , Rowen Seckold , Tuba Seven Menevşe , Peter Simm , Anna Simon , Marco Spada , Athanasia Stoupa , Lilla Szeifert, Davide Tonduti , Hans van Toor, Serap Turan , Joel Vanderniet , Monique de Waart, Ronald van der Wal, Adri van der Walt , Anne-Marie van Wermeskerken , Jolanta Wierzba , Federica Zibordi , Amnon Zung , Robin P Peeters , W Edward Visser
Abstract
Context: Patients with mutations in thyroid hormone transporter MCT8 have developmental delay and chronic thyrotoxicosis associated with being underweight and having cardiovascular dysfunction.
Objective: Our previous trial showed improvement of key clinical and biochemical features during 1-year treatment with the T3 analogue Triac, but long-term follow-up data are needed.
Methods: In this real-life retrospective cohort study, we investigated the efficacy of Triac in MCT8-deficient patients in 33 sites. The primary endpoint was change in serum T3 concentrations from baseline to last available measurement. Secondary endpoints were changes in other thyroid parameters, anthropometric parameters, heart rate, and biochemical markers of thyroid hormone action.